And it's not just melanoma! Midkine has been implicated in metastasis for other cancers too, like breast cancer, lung cancer, colorectal cancer, and hepatocellular carcinoma. This work, therefore, has broader implications beyond just melanoma! #CancerResearch #MetastasisPrevention

Crucially, we found that combining an NR2F1 agonist with an MDK inhibitor could be a potential therapeutic strategy to prolong the dormancy phase of melanoma DCCs, preventing metastasis formation! Big implications for future treatments. #Science #CancerTreatment

This study reveals the growth factor Midkine (MDK) triggers a potent autocrine mechanism that deactivates NR2F1-dependent dormancy in DCCs, favoring metastatic outgrowth. This means MDK essentially "wakes up" dormant melanoma cells! #MIDKINE #NR2F1 #DDCs

Why is this important? Melanoma recurrence often comes from dormant cancer cells (DCCs) "waking up" to form metastases, sometime years after primary tumor was removed. We've known NR2F1 drives dormancy , but how DCCs reactivate has been puzzling. #Dormancy

So excited and proud to be a co-author on our new preprint: "Midkine inhibits dormancy of disseminated melanoma cells." Huge congrats to Carolina Rodriguez-Tirado & Maria Soledad Sosa for leading this fantastic work! 🎉 #MelanomaResearch #CancerDormancy #Midkine

Midkine inhibits dormancy of disseminated melanoma cells A significant factor in cancer-related mortality in melanoma is the appearance of intrinsically aggressive distal metastases. This recurrence frequently results from the awakening of dormant dissemina...

I’m thrilled to announce our project on skin melanoma dormancy. Congratulations to all the authors! Now, let’s embark on the journey to get our work published in a journal! www.biorxiv.org/cgi/content/...
@einsteinmededu.bsky.social @cdi-einstein.bsky.social